Epinephrine
Q&A: Joint task force updates anaphylaxis practice parameter
A joint task force has published an updated, evidence-based practice parameter for diagnosing and treating anaphylaxis in Annals of Allergy, Asthma & Immunology.
Top in allergy/asthma: Phone screen protector triggers allergy; Q&A on Flovent generics
After a woman developed a rash on her face and fingers several times, her doctors discovered the cause was her cell phone, specifically the acrylate screen protector on her cell phone.
Hospital type, region significant predictors for observation time following anaphylaxis
Most EDs do not have specific guidelines for observation time following anaphylaxis, and the average duration depends largely on comorbidities and the type of hospital, according to a survey study.
Q&A: Epinephrine nasal spray may overcome autoinjector limitations
An intranasal epinephrine spray produced pharmacokinetic and pharmacodynamic results that were comparable or superior to intramuscular injections, according to a study published in The Journal of Allergy and Clinical Immunology: Global.
Nasal epinephrine spray outcomes comparable with autoinjector, manual injections
An intranasal epinephrine spray produced pharmacokinetic and pharmacodynamic results that were comparable or superior to intramuscular injections, according to a study published in The Journal of Allergy and Clinical Immunology: Global.
VIDEO: FDA-requested study of epinephrine nasal spray underway
ANAHEIM, Calif. — ARS Pharma is conducting an additional clinical trial of its neffy epinephrine nasal spray per FDA request, company cofounder, president and CEO Richard Lowenthal, MS, MSEL, told Healio.
Joint task force releases anaphylaxis, atopic dermatitis treatment parameters
Two new practice parameters from a joint task force published in Annals of Allergy, Asthma & Immunology provide evidence-based recommendations for the diagnosis and management of anaphylaxis and atopic dermatitis.
Customer discovery reveals why patients do not carry their epinephrine autoinjectors
ANAHEIM, Calif. — Inconvenience and forgetfulness are among the reasons why people do not always carry their epinephrine autoinjectors, according to a poster at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
Top in allergy/asthma: Evolution of anaphylaxis management; drug allergy de-labeling
At the American College of Allergy, Asthma & Immunology Annual Scientific Meeting, Jay A. Lieberman, MD, FACAAI, discussed upcoming changes to anaphylaxis guidelines and treatment strategies, including new epinephrine delivery methods.
Epinephrine concentrations after injection decrease with greater BMI
ANAHEIM, Calif. — There was a significant negative relationship between epinephrine exposure via injection and BMI, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.